The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used and Rental copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
In 1943, Albert Schatz, a young Rutgers College Ph.D. student, worked on a wartime project in microbiology professor Selman Waksman's lab, searching for an antibiotic to fight infections on the front lines and at home. In his eleventh experiment on a common bacterium found in farmyard soil, Schatz discovered streptomycin, the first effective cure for tuberculosis, one of the world's deadliest diseases. However, Waksman took credit for the discovery and secretly enriched himself with royalties from the streptomycin patent. In an unprecedented lawsuit, young Schatz sued Waksman, and was awarded the title of "co-discoverer" and a share of the royalties. But two years later, Professor Waksman alone was awarded the Nobel Prize. Schatz disappeared into academic obscurity. For the first time, acclaimed author and journalist Peter Pringle unravels the intrigues behind one of the most important discoveries in the history of medicine. The streptomycin patent was a breakthrough for the drug companies, overturning patent limits on products of nature and paving the way for today's biotech world. As dozens more antibiotics were found, many from the same family as streptomycin, the drug companies created oligopolies and reaped big profits. Pringle uses firsthand accounts and archives in the United States and Europe to reveal the intensely human story behind the discovery that started a revolution in the treatment of infectious diseases and shaped the future of Big Pharma.
Peter Pringle is a veteran British foreign correspondent and the author of several nonfiction books, including Food, Inc. and Those Are Real Bullets, Aren't They? He has written for the New York Times, the Washington Post, the Atlantic, and the Nation.